Upgrade to SI Premium - Free Trial

Exact Sciences (EXAS) PT Raised to $38 at BofA/Merrill Lynch; 'Evidence Counters Bear Thesis on Commercial Rates'

June 12, 2017 8:45 AM
BofA/Merrill Lynch raised its price target on Exact Sciences (NASDAQ: EXAS) to $38.00 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst EPS Change Analyst EPS View Analyst PT Change Corporate News FDA Short Sales

Next Articles